Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia

BACKGROUND: A single‐arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T‐cell–engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rambaldi, Alessandro, Ribera, Josep‐Maria, Kantarjian, Hagop M., Dombret, Hervé, Ottmann, Oliver G., Stein, Anthony S., Tuglus, Catherine A., Zhao, Xiaoyue, Kim, Christopher, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003760/
https://www.ncbi.nlm.nih.gov/pubmed/31626339
http://dx.doi.org/10.1002/cncr.32558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003760/
https://www.ncbi.nlm.nih.gov/pubmed/31626339
http://dx.doi.org/10.1002/cncr.32558

Ejemplares similares